Key clinical point: Long-term treatment with oral rimegepant, taken as needed (PRN) or every other day (EOD) plus PRN on nonscheduled days, reduced the need for analgesics or antiemetics in adults with migraine.
Major finding: The proportion of participants who stopped using analgesics or antiemetics after the pre-treatment observation period increased during weeks 1-4 (36.9%), 5-8 (52.6%), and 9-12 (56.5%) following rimegepant treatment in both PRN and PRN plus EOD cohorts.
Study details: This post hoc analysis of an open-label study included 1800 adults with migraine who received rimegepant PRN (n = 1514) or EOD plus PRN (n = 286) for 3 months according to the frequency of attacks, and of whom 80.1% used analgesics or antiemetics during the 30-day pre-treatment observation period.
Disclosures: This study was funded by Biohaven (acquired by Pfizer in October 2022). Terence Fullerton and Glenn Pixton declared being full-time employees of and holding stocks or options in Pfizer, and Glenn Pixton also declared holding stocks in Abbvie.
Source: Fullerton T, Pixton G. Long-term use of rimegepant 75 mg for the acute treatment of migraine is associated with a reduction in the utilization of select analgesics and antiemetics. J Pain Res. 2024;17:1751-1760 (May 2). doi: 10.2147/JPR.S456006 Source